只翻译了一部分，希望可以帮助大家理解昨晚的讲课。

幻灯片1
High Grade B-cell Lymphomas with MYC Abnormalities Respond Poorly to R-CHOP Regardless of whether the Morphologic or Immunophenotypic Features are Consistent with Atypical Burkitt Lymphoma
有MYC基因异常的高级别B细胞淋巴瘤对R-CHOP反应差，不管其形态学或免疫表型是否与不典型Burkitt淋巴瘤（ABL）一致

幻灯片2
> High Grade B-Cell Lymphomas that do not meet the WHO criteria for BL can be difficult to classify不符合WHO中BL诊断标准的高级别B细胞淋巴瘤，难以分类
Diffuse Large B-cell Lymphoma versus Atypical Burkitt Lymphoma?弥漫大B细胞淋巴瘤（DLBCL）/Burkitt淋巴瘤（ABL）？
> Case is often signed out as “HGBCL, Favor   DLBCL or Atypical BL”,  with an addendum issued, after MYC result becomes available 病例常常报告为“高级别B细胞淋巴瘤，倾向于DLBCL或ABL”，在可以MYC检测之后存在一个遗留问题
> R-CHOP versus more intensive regimens (e.g. Hyper-CVAD)?R-CHOP还是更强化疗(如Hyper-CVAD)?
译注：R-CHOP指利妥昔单抗联合环磷酰胺、阿霉素、长春新碱和强的松联合化疗方案。Hyper-CVAD指高分次量环磷酰胺、长春新碱、多柔比星和地塞米松联合化疗方案。

幻灯片4
MYC
> Transcription Factor located at 8q24定位于8q24的转录因子
> Basic-helix-loop-helix-leucine zipper family碱性螺旋-环-螺旋锌指蛋白家族
> Activates transcription through multiple mechanisms通过多种机制激活转录
> Regulates genes involved in cell cycle control, apoptosis, protein synthesis, cell adhesion, metabolism调控与细胞周期控制、凋亡、蛋白质合成、细胞粘附和代谢等功能有关的基因
> Dysregulated in up to 20% of malignancies恶性肿瘤中高达20%存在调控异常

幻灯片29
Conclusions
> MYC+ and MYC- HGBCL span a morphologic and immunophenotypic spectrum MYC+和MYC-的高级别B细胞淋巴瘤有广阔的形态学和免疫表型谱
> MYC+ HGBCL have a poor response to R-CHOP, but often show good responses to intensive therapy even if some features are inconsistent with BL. A low threshold for testing MYC status is warranted. MYC+的高级别B细胞淋巴瘤，对R-CHOP反应差，但对更强化疗（如Hyper-CVAD）反应好
> MYC- HGBCL are heterogeneous and a subset of this group may not respond to even intensive treatment. Novel therapies are needed. MYC-的高级别B细胞淋巴瘤为异质性，其中一些对强化疗反应也差，需要探索新的化疗

鼓掌